Dongnao Medical Completes Seed Funding Round to Pioneer 'Brain-Computer Interface + High-End Medical Devices' Sector

Recently, Dongnao Medical Technology (Tianjin) Co., Ltd. (hereinafter referred to as "Dongnao Medical") announced the completion of its seed round financing, which was exclusively invested by Tianjin Heying Haihe Brain-Machine Fund.

Dongnao Medical Focuses on Innovations in Non-Invasive Brain Function Monitoring Technology, Aiming to Accelerate the Clinical Application of Cutting-Edge Technologies Such as Brain-Computer Interfaces and Artificial Intelligence. Through Technological Innovation, Dongnao Medical Provides Precise Support for Brain Health Management. The investment from Tianjin He Ying Haihe Brain-Computer Interface Fund not only recognizes Dongnao Medical's technological leadership but also marks its strategic elevation from "Brain Function Monitoring Innovator" to "Co-Builder of the Brain-Computer Interface Ecosystem."

It is worth mentioning that Dongnao Medical is an incubated enterprise of the Haihe Laboratory of Brain-Computer Interaction and Human-Machine Symbiosis. Supported by the laboratory's top research team, it has made breakthroughs in technology development and clinical applications. The team possesses internationally leading technical advantages in areas such as the mechanisms of neurocritical brain diseases, rapid diagnosis and minimally invasive treatment, clinical translation of brain-computer interfaces in intensive care, and a series of non-invasive physiological monitoring directions including intracranial pressure and cerebral perfusion.

Dongnao Medical focuses on the clinical urgent need for "non-invasive, real-time, and precise" monitoring of core parameters such as cerebral oxygenation, intracranial pressure, blood pressure, and hemodynamics. It has built a complete product matrix ranging from single-item monitoring to multi-parameter integration, including at least four products that are global firsts. The company's core products have completed the critical certification phase and are steadily advancing into the cutting-edge brain-computer interface market.

This round of financing will mainly be used to accelerate the large-scale promotion of certified products, clinical validation of globally pioneering products under development, and the deep accumulation of brain-computer fusion monitoring technology. Dongnao Medical will embark on a new journey of "brain-computer + high-end medical devices," accelerating the clinical transformation of cutting-edge technologies such as brain-computer interfaces and artificial intelligence, using technological innovation to precisely safeguard brain health management.

The rapid development of Dongnao Medical stems from its confidence in self-researched innovative technical capabilities and its original intention to address clinical pain points with the utmost precision.

1. Technological innovation capabilities are globally leading, with multiple products being the world's first. Dongnao Medical benchmarks against the international cutting-edge technology in the industry, achieving several "from 0 to 1" breakthroughs. It has reached or even surpassed international advanced levels in technological directions such as cerebral oxygen monitoring based on the new generation of near-infrared spectroscopy (NIRS) detection technology and non-invasive intracranial pressure monitoring based on the ICP-absorbance model. The team’s development of non-invasive intracranial pressure brain-computer monitoring technology has overcome the challenge of invasive operations—a "bottleneck" problem. This is a global first, completely breaking the physical limitations of traditional invasive probes and establishing a brand-new technical paradigm.

II. Fully Independent and Controllable Core Technologies, a Solid Foundation for Safety. Dongnao Medical insists on full-chain independent research and development from underlying algorithms to key components, from complete machine systems to supporting consumables. Whether it is the core technologies in cerebral oxygen monitoring, intracranial pressure monitoring, or forward-looking exploration of hemodynamic parameters, all are fully owned intellectual property of the company. To date, the company has applied for multiple technical patents around key nodes such as core algorithms, monitoring methods, sensor structures, and monitoring systems, forming a tight patent technology protection network. This ensures complete independent control over technological updates, iterative progress, and the safety of the entire product chain production, contributing to the reverse export of China's high-end brain-machine products to the global market.

III. Bidirectional Empowerment between Medicine and Engineering: From Clinical Practice to Clinical Application. Since its establishment, Dongnao Medical has been committed to addressing clinical pain points, collaborating deeply with neurosurgery, intensive care medicine, and anesthesiology departments of leading tertiary hospitals in China. The rapid iteration of the non-invasive cerebral oxygen monitor from 2 channels to 8 channels stems from real feedback by medical staff during surgery and in critical care scenarios — enabling precise monitoring of systemic oxygen levels and fully meeting clinical needs. The development of the intracranial pressure-cerebral oxygen synchronized monitoring system addresses the combined clinical need for simultaneous monitoring of intracranial pressure and cerebral oxygen, eliminating the hassle of operating multiple devices, offering greater convenience and cost-effectiveness. The creation of the BIS + cerebral oxygen dual-purpose electrode directly responds to clinicians' feedback about limited forehead space and complex wiring, making the electrode compact, accurate, and more practical. The integration of medical and engineering expertise is not only Dongnao Medical’s approach to R&D but also a solid guarantee that their products address clinical challenges and serve both doctors and patients.

Dongnao Medical has achieved a systematic product layout from single-parameter monitoring to multi-parameter fusion, from local monitoring to whole-body assessment, and from equipment to consumables. In the field of cerebral oxygen monitoring, the company's first cornerstone product, a non-invasive cerebral tissue oxygen monitor, has successfully obtained certification and been launched in the market. Based on self-developed next-generation near-infrared spectroscopy technology, it achieves precise monitoring from local cerebral oxygen to whole-body oxygen levels, with accuracy surpassing similar products currently available. In the field of intracranial pressure (ICP) monitoring, the company’s globally pioneering non-invasive ICP monitor uses an exclusive ICP-absorbance model. With just forehead electrode patches, it enables continuous dynamic monitoring, completely revolutionizing traditional invasive techniques, greatly enhancing safety, reducing patient discomfort and infection risks, and drawing widespread industry attention. In the area of multi-parameter fusion, the company is deeply developing two globally first-of-their-kind products: an integrated ICP-cerebral oxygen synchronized monitoring system and a Bispectral Index (BIS) + cerebral multi-parameter monitoring device, which enable the unified collection and fusion analysis of core indicators. In terms of consumable innovation, the world's first "BIS + cerebral oxygen" dual-purpose electrode patch integrates anesthesia depth evaluation and cerebral oxygen monitoring, not only saving space on the forehead that would be occupied by separate patches but also simplifying doctors’ operational procedures while reducing costs for patients. Regarding cutting-edge technology reserves, the development of a cuff-less real-time non-invasive blood pressure monitor and a non-invasive real-time arterial blood pressure and hemodynamic monitoring system capable of tracking 13 parameters is accelerating, contributing to advancements in hemodynamic monitoring and assessment.

Four globally pioneering products, full-chain independent intellectual property rights, covering all scenarios from neurocritical care to the perioperative period — Dongnao Medical transitions from "focused expertise" to "system integration," exploring the limitless possibilities of non-invasive brain function monitoring.

The investment in Dongnao Medical by Tianjin Heying Haihe Brain-Machine Fund not only serves as an authoritative certification of Dongnao Medical's "independently developed leading technology," but also becomes a key engine for the team to shift from research and development to deep market penetration. Standing at a new starting point, Dongnao Medical is building a strong foundation on technological innovation and deeply expanding into multiple segments of the brain-machine industry, achieving “1+N” industrial acceleration and helping China’s "brain-machine + high-end medical devices" gain a foothold in the international arena.

For this round of financing,Founder of Dongnao Medical, Wang Binzhe"This round of financing is a milestone for Dongnao Medical as it transitions from 'innovative exploration' to 'value implementation.' We have always believed that the starting point of medical innovation lies in clinical needs, and its ultimate goal is to benefit patients. The investment from Tianjin Heping Haihe Brain-Computer Fund not only provides us with sufficient resources to accelerate product implementation but also integrates us into China's top brain-computer interface industry ecosystem. As a Tianjin-based technology enterprise, we feel a profound sense of responsibility. Moving forward, we will focus on two key priorities: First, 'implementation,' ensuring that our approved and soon-to-be-approved products quickly enter medical institutions at all levels across China, using solid clinical data to build a strong reputation and truly benefit patients. Second, 'technology,' diving deep and taking root to thoroughly advance and perfect non-invasive brain monitoring. We aim to achieve what others have not, create something entirely our own, and develop innovations that genuinely assist clinical practice. Step by step, through a series of internationally pioneering achievements, we will drive the rapid adoption of Tianjin’s brain-computer technology in the global medical field, delivering a robust answer for China’s brain-computer interface initiatives."

Zhang Yutao, Partner of Tianjin Heying Haihe Brain-Machine Fund"It shows that neurocritical care is an essential medical need, and non-invasive monitoring technology is an industry trend. The separate project initiation by the National Healthcare Security Administration for neural monitoring and brain-computer interfaces is a testament to this. Dongnao Medical focuses on the implementation and application of non-invasive intracranial pressure and non-invasive cerebral oxygen monitoring technologies, forming an important piece of the Tianjin Heying Haihe Brain Machine Fund's cognitive, analytical, and detection puzzle for the brain. This technology represents a cutting-edge convergence point of neuroscience, biomedical engineering, and critical care medicine, meeting rigid clinical demands, showcasing hardcore technical barriers, and holding explosive industrial potential. Core barriers exist in signal perception, algorithmic decoding, multimodal fusion, and clinical validation. At the same time, Dongnao Medical achieves technological breakthroughs and industrial practices through the Brain-Computer Interaction and Human-Machine Symbiosis Haihe Laboratory, realizing independent innovation and breaking through four-dimensional barriers in technology, patents, clinical applications, and industry. In the future, we will strive together to provide safer, more efficient, and more dignified medical care for hundreds of millions of patients."

The Brain-Computer Interaction and Human-Machine Fusion Haihe Laboratory, the sixth Haihe Laboratory established by Tianjin City in alignment with national laboratory standards, is led by Tianjin University. It brings together academicians and national-level talents to form an elite interdisciplinary team (neuroscience, computer science, medicine, materials). As a top strategic technology platform in China’s brain-computer interface field, it has built a fully localized industrial chain system encompassing "devices-chips-algorithms-platforms-systems-applications." Its core research areas include novel neural signal sensing theories and detection methods, biomimetic tissue-engineered nerves, key technologies for next-generation high-throughput brain-computer interaction, and fundamental core components for human-machine fusion. It has achieved internationally leading levels in multiple core metrics of non-invasive brain-computer interfaces.

It is the first industrial fund in China that focuses on the development of the brain-computer interface industry, with an initial scale of 1 billion yuan. In line with the strategic industrial layout of the Tianjin Municipal Committee and the municipal government, and relying on the Haihe Laboratory of Brain-Computer Interaction and Human-Machine Symbiosis, it was initiated by Profit Together Capital and the China Electronics Group system, jointly established with the Haihe Industrial Fund of Tianjin City and the High-Tech Zone of Binhai New Area of Tianjin City. It is committed to promoting the industrialization and ecological integration of brain-computer interfaces through investment, providing systematic empowerment from R&D support to industrial implementation, with the vision of becoming a key contributor to China's brain-computer interface industry.